ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was honored with two Gold Stevie ® Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals. Harvey J. Berger, M.D., founder, chairman and chief executive officer of ARIAD, accepted the awards at the 11th Annual American Business Awards℠ in Chicago last night. The American Business Awards are the nation’s premier business awards program. All organizations operating in the United States are eligible to submit nominations – public and private, for-profit and non-profit, large and small.
“The recognition of ARIAD through these two Stevie Awards at the same time represents the culmination of more than twenty years of dedication to ARIAD’s vision -- to transform the lives of cancer patients with breakthrough medicines,” stated Dr. Berger. “All of our employees are to be commended for their contributions that led to ARIAD being named Company of the Year. Personally, I am humbled by the recognition as Pharmaceutical Executive of the Year by the American Business Awards.”
Nicknamed the Stevies for the Greek word for “crowned,” the trophies were presented to honorees during a gala event on Monday, June 17 at the Fairmont Chicago Millennium Park Hotel. More than 500 nominees and their guests attended. The presentations will be broadcast this week by the Business TalkRadio Network on Wednesday and Thursday nights.
More than 3,200 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.“This year’s American Business Awards was outsized in every way,” said Michael Gallagher, Stevie Awards founder and president. “More entries and more judges than ever before, and I’d have to say the most impressive collection of nominations we’ve ever received. We congratulate all of this year’s Stevie winners for their outstanding work.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts